Research
Print page Print page
Switch language
Bispebjerg Hospital - a part of Copenhagen University Hospital
Published

Omalizumab for cholinergic urticaria: 6 months prospective study and systematic review of the literature

Research output: Contribution to journalReviewResearchpeer-review

DOI

  1. Certolizumab pegol for hidradenitis suppurativa: Case report and literature review

    Research output: Contribution to journalLetterResearchpeer-review

  2. Effectiveness and safety of switching from originator to biosimilar adalimumab in patients with psoriasis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Fluctuations in serum levels of adalimumab and infliximab in patients on stable treatment for psoriasis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Reduction in actinic keratoses following 9-valent human papilloma virus vaccination

    Research output: Contribution to journalLetterResearchpeer-review

  5. Dupilumab for prurigo nodularis: Case series and review of the literature

    Research output: Contribution to journalReviewResearchpeer-review

  1. Effective clinical study recruitment of patients with atopic dermatitis through social media

    Research output: Contribution to journalLetterResearchpeer-review

  2. Airway hyperresponsiveness to inhaled mannitol identifies a cluster of non-eosinophilic asthma patients with high symptom burden

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Impact of white balance adjustment on evaluation of photographs of atopic dermatitis lesions

    Research output: Contribution to journalLetterResearchpeer-review

  4. Increased all-cause mortality in concomitant atopic dermatitis and asthma: A nationwide registry-based study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

To examine the effectiveness of omalizumab on disease activity and quality of life in patients with cholinergic urticaria (CholU). Further, a systematic review of the literature was performed to identify all studies of use of omalizumab in CholU. A total of 23 patients (63.9%) were refractory to updosed non-sedating antihistamines and initiated omalizumab in the observation period. Among these, an improvement of 10.8 UAS7 points (4.6-17.0), P = .002, was seen at 6 months follow up. DLQI and disease bother score VAS also improved significantly from before initiating treatment with omalizumab to follow-up; 7.0 points (3.6-10.3), P < .001 and 3.1 points (1.5-4.8), P = .001, respectively. The overall mean drug survival time for omalizumab (discontinued due to any cause) was 30.6 months (22.2-39.0). A total of five patients (21.7%) reported suspected side effects (headache, muscle pain, fatigue and injection site reactions) during treatment with omalizumab until 6 months follow-up. The systematic literature review identified 58 additional antihistamine refractory patients with CholU treated with omalizumab. The available studies reported that omalizumab is effective in patients with CholU and improves their disease-related quality of life. Omalizumab is safe, reduces disease activity and improves disease-related quality of life in patients with CholU.

Original languageEnglish
Article numbere14010
JournalDermatologic Therapy
Volume33
Issue number6
Pages (from-to)e14010
ISSN1396-0296
DOIs
Publication statusPublished - Nov 2020

    Research areas

  • anti-IgE, cholinergic urticaria, omalizumab, systematic review

ID: 61720393